Skylar Jeremias


Cate Lockhart Explores the Evolution of Biosimilar Barriers

October 26, 2021

Reimbursement concerns and the uncertainty of how interchangeability will impact biosimilar adoption are hot-button issues in the biosimilar space, Cate Lockhart, PharmD, PhD, MS, explains in this interview.

Gary Lyman, MD, MPH, Explores the Progress With Oncology Biosimilars

October 17, 2021

Oncology biosimilars are broadly in use for good reason: They're absolutely vital for cost reduction and access, but efforts are needed to promote uptake of these agents, says Gary Lyman, MD, MPH, in this interview.

Ivo Abraham, PhD, Discusses G-CSF Biosimilars, Such as Neulasta Onpro

October 11, 2021

Ivo Abraham, PhD, a professor with University of Arizona Health Sciences in the Department of Pharmacy Practice, outlines the current trajectory and savings potential for granulocyte-colony stimulating factor (G-CSF) biosimilars and Neulasta Onpro (pegfilgrastim).